Swiss Strategy Launches "CYTISUS" Herbal Cigarettes - An Effective Alternative To Cigarettes

ZURICH, Swaziland - March 18, 2023 - PRLog -- Swiss Strategy Aktiengesellschaft has announced the launch of "CYTISUS" herbal cigarettes, a tobacco-free and nicotine-free alternative to traditional cigarettes. The all-natural menthol cigarettes are medicated with naturally-occurring Cytisine, derived from the Cytisus laburnum plant, which has been found to be effective in several randomized clinical trials for smoking cessation.

Cytisine, also known as baptitoxine, cytisinicline, or sophorine, is an alkaloid that occurs naturally in several plant genera, such as Laburnum and Cytisus of the family Fabaceae. It has been used medically to help with smoking cessation. CYTISUS cigarettes are a partial agonist of the α4β2 nicotinic acetylcholine receptor, responsible for central effects of nicotine. Cytisine is primarily derived from the Cytisus laburnum plant which inspired the development of CHANTIX (varenicline tartrate) a non-nicotine prescription medicine that was developed by Pfizer, Inc. specifically to help people quit smoking. The efficacy of CHANTIX in smoking cessation is believed to be the result of varenicline's activity at α4β2 subtype of the nicotinic receptor.

The leaves of Cytisus laburnum, or the golden rain tree, were used as a tobacco substitute by soldiers in World War II, and research in eastern Europe, Russia and Germany over the past 40 years showed that cytisine was effective in helping smokers stop smoking. CYTISUS cigarettes offer a viable alternative to traditional cigarettes and may help smokers quit smoking.

Swiss Strategy Aktiengesellschaft is committed to providing a more efficacious α4β2 receptor partial agonist for the treatment of nicotine addiction and smoking cessation. The launch of CYTISUS cigarettes is a step in that direction.

About Swiss Strategy A.G.

Swiss Strategy A.G. is a Swiss marketing firm. Its role is to promote science-based innovations in the public interest for the economy and society in Switzerland. Swiss Strategy A.G. promotes limited partnerships between motivated scientists and the Swiss marketplace with inspiring patented inventions for successful Swiss start-ups as well as innovative products and services.

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

For more info, please visit https://swissstrategy.webnode.co.uk

Investor Relations:

Marina Krueger, Ph.D.

Chief Medical Officer

Swiss Strategy Aktiengesellschaft

Schützenmattstrasse 71

CH-8180 Bülach, Switzerland

Tel.: +41 79 123 57-84

Email: marinakrueger@dayrep.com

SOURCE Swiss Strategy A.G.

Federal Office of Public Health, Switzerland and The SmokeFree campaign of Switzerland

https://www.youtube.com/watch?v=H3VQVYyoIuk